Cargando…

Surgery for Non-Small Cell Lung Cancer in the Personalized Therapy Era

Detalles Bibliográficos
Autores principales:	Chiappetta, Marco, Sassorossi, Carolina, Cusumano, Giacomo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453037/ https://www.ncbi.nlm.nih.gov/pubmed/37623044 http://dx.doi.org/10.3390/curroncol30080563

Ejemplares similares

External Validation of a Prognostic Score for Survival in Lung Carcinoids
por: Chiappetta, Marco, et al.
Publicado: (2022)

Induction treatment in operable non-small cell lung cancer: the immune oncology era unfolds
por: Walker, Paul R.
Publicado: (2023)

Small Cell Lung Cancer: A New Era Is Beginning?
por: Morabito, Alessandro, et al.
Publicado: (2021)

The Long Run towards Personalized Therapy in Non-Small-Cell Lung Cancer: Current State and Future Directions
por: Genova, Carlo
Publicado: (2023)

Intraoperative molecular imaging in thoracic oncology: pushing the boundaries of precision resection for occult non-small cell lung cancer in the era of minimally invasive surgery
por: Azari, Feredun, et al.
Publicado: (2022)

Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine
por: Tabchi, Samer, et al.
Publicado: (2017)

Surgery for stage IV non-small cell lung cancer?
por: Puig, Carlos A., et al.
Publicado: (2020)

Immunotherapy as a targeted therapy in non-small cell lung cancer
por: Rocco, Danilo, et al.
Publicado: (2019)

Could the clinical target volume be omitted for radiotherapy of locally advanced non-small cell lung cancer in the modern era?
por: Verma, Vivek, et al.
Publicado: (2021)

Operable non-small cell lung cancer: induction therapy, adjuvant therapy, or both?
por: Agrafiotis, Apostolos C., et al.
Publicado: (2023)

The Treatment of Metastatic Non-Small Cell Lung Cancer in a New Era of Personalized Medicine
por: Hirsh, Vera
Publicado: (2015)

TTF-1 and immune checkpoint therapy in non-small cell lung cancer
por: Gumbleton, Matthew, et al.
Publicado: (2023)

Targeted therapy and non-small cell lung cancer: a new era!
por: Malapelle, Umberto, et al.
Publicado: (2019)

Improving Cardiovascular Outcomes: The Era of Personalized Therapy in Atherosclerosis
por: Kabłak-Ziembicka, Anna
Publicado: (2022)

Neoadjuvant gefitinib therapy: a potential standard therapy for non-small cell lung cancer
por: Nishida, Tomoki, et al.
Publicado: (2022)

Surgery in limited-disease small-cell lung cancer
por: Koul, Parvaiz A.
Publicado: (2012)

Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine
por: Soldera, Sara Victoria, et al.
Publicado: (2017)

Emerging Biomarkers in the Era of Personalized Cancer Medicine
por: Ricciuti, Biagio, et al.
Publicado: (2019)

The management strategy of pancreatic cancer in the era of systemic therapy—“Surgery First” or “Surgery Last”?
por: Yang, Yinmo, et al.
Publicado: (2022)

Melanoma: the role of surgery in the era of new therapies
por: Mozzillo, Nicola, et al.
Publicado: (2014)

Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer
por: Dienstmann, Rodrigo, et al.
Publicado: (2011)

Systemic immune-inflammation index and prognosis of advanced non-small cell lung cancer
por: Alifano, Marco
Publicado: (2020)

Proton stereotactic body radiation therapy for non-small cell lung cancer
por: Diwanji, Tejan, et al.
Publicado: (2020)

Optimizing adjuvant therapy in EGFR-mutated non-small cell lung cancer
por: Shepherd, Annemarie F., et al.
Publicado: (2020)

Personalized cancer medicine: next steps in the genomic era
por: Derks, S., et al.
Publicado: (2015)

Personalized cancer supportive care in COVID-19 era
por: Lyman, G.H., et al.
Publicado: (2020)

Personalized Care for Patients with Cancer in the Precision-Medicine Era
por: Lopes-Júnior, Luís Carlos, et al.
Publicado: (2023)

Evolution in the management of non-small cell lung cancer in Brazil
por: Fernandes, Caio Júlio Cesar dos Santos
Publicado: (2017)

Realities of KRAS-mutated non-small cell lung cancer
por: Min, Young Joo
Publicado: (2017)

Immunotherapy in non-small cell lung cancer: advancements and challenges
por: Zhou, Fei, et al.
Publicado: (2021)

Resectable non-small cell lung cancer: an evolving landscape
por: Loh, Jerold, et al.
Publicado: (2022)

Lung cancer treatment in the era of immunotherapy
por: Xu, Yang, et al.
Publicado: (2020)

Prognostic Factors and Long-Term Survival in Locally Advanced NSCLC with Pathological Complete Response after Surgical Resection Following Neoadjuvant Therapy
por: Lococo, Filippo, et al.
Publicado: (2020)

The not so small role of adjuvant chemotherapy in resected non-small cell lung cancer
por: Almquist, Daniel R., et al.
Publicado: (2021)

Optimal Therapy for Advanced Non-Small Cell Lung Cancer Without Driver Alterations
por: Pacheco, Jose, et al.
Publicado: (2021)

Leading New Frontiers in Vulva Cancer to Build Personalized Therapy
por: Corrado, Giacomo, et al.
Publicado: (2022)

Era of Personal Health Records in Korea
por: Lee, Jae-Ho
Publicado: (2022)

Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer
por: Sundar, Raghav, et al.
Publicado: (2017)

Adjuvant TKI therapy in resected EGFR-mutant non-small-cell lung cancer—ready for prime time?
por: Arulananda, Surein, et al.
Publicado: (2020)

BRAF Mutations and Resistance of Non-Small Cell Lung Cancer to BRAF-Targeted Therapies Using Liquid Biopsy
por: Li, Ming, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jrrkihv0sdqhu5uq8idc6q6o07